Mitoxantrone
Information
- Drug Name
- Mitoxantrone
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Antagonistic combinations with imexon included mit... | ROS1 | ROS1 OVEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| As regards mitoxantrone, ABCB5 was not found to be... | ABCB5 | ABCB5 UNDEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02553460 | Active, not recruiting | Phase 1/Phase 2 | Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I | January 29, 2016 | October 2031 |
| NCT03164057 | Active, not recruiting | Phase 2 | A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | June 15, 2017 | June 2027 |
| NCT02303821 | Active, not recruiting | Phase 1 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | February 16, 2015 | July 14, 2024 |
| NCT02688140 | Active, not recruiting | Phase 3 | Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia | June 2016 | January 2025 |
| NCT02632708 | Active, not recruiting | Phase 1 | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | December 31, 2015 | July 2024 |
| NCT02101853 | Active, not recruiting | Phase 3 | Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia | December 17, 2014 | September 22, 2024 |
| NCT00169208 | Completed | Phase 2 | Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma | April 2001 | December 2006 |
| NCT00193479 | Completed | Phase 2 | Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma | April 2003 | February 2010 |
| NCT00199069 | Completed | Phase 4 | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) | April 1993 | May 2001 |
| NCT00254410 | Completed | Phase 2 | FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years | March 14, 2005 | September 14, 2017 |
| NCT00290511 | Completed | Phase 2 | Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma | June 29, 2004 | February 12, 2021 |
| NCT00304291 | Completed | Phase 4 | A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease) | August 2001 | May 2004 |
| NCT00408278 | Completed | Phase 4 | Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) | July 2005 | December 2013 |
| NCT00417079 | Completed | Phase 3 | XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer | January 2007 | September 2009 |
| NCT00436839 | Completed | Phase 3 | Taxotere Prostate Cancer New Indication Registration Trial in China | January 2007 | June 2012 |
| NCT00004001 | Completed | Phase 3 | S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy | October 1999 | January 2007 |
| NCT00109837 | Completed | Phase 2 | S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | April 2005 | November 2014 |
| NCT00119730 | Completed | Phase 2 | Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma | February 2005 | December 2013 |
| NCT00124566 | Completed | Phase 2 | Study of Irofulven in Patients With Hormone-refractory Prostate Cancer | June 2004 | December 2009 |
| NCT00143975 | Completed | Phase 2 | Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM) | June 2004 | June 2009 |
| NCT00151255 | Completed | Phase 3 | All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia | June 2004 | January 2011 |
| NCT00512252 | Completed | Phase 1/Phase 2 | AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia | July 2007 | June 2010 |
| NCT00526305 | Completed | Phase 4 | LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive | January 2000 | April 2005 |
| NCT00556127 | Completed | Phase 2 | Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma | June 2002 | September 2006 |
| NCT00656084 | Completed | Phase 2 | Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell | December 2004 | January 2008 |
| NCT00661492 | Completed | Phase 2 | Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC) | May 2008 | June 2011 |
| NCT00683475 | Completed | Phase 2 | A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer | August 2008 | September 2011 |
| NCT00744081 | Completed | Phase 2 | Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) | July 2004 | December 2010 |
| NCT00770848 | Completed | Phase 1/Phase 2 | AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer | November 2008 | April 2012 |
| NCT00774046 | Completed | Phase 2 | High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML | December 2002 | March 2011 |
| NCT00842595 | Completed | Phase 2 | Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas | December 2003 | May 2010 |
| NCT00853008 | Completed | Phase 4 | Treatment of High Risk Adult Acute Lymphoblastic Leukemia | January 2003 | December 2012 |
| NCT00906945 | Completed | Phase 1/Phase 2 | Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia | February 2011 | September 2015 |
| NCT01004497 | Completed | Phase 2 | First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL | March 2010 | April 2015 |
| NCT01184898 | Completed | N/A | Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) | July 2010 | February 2016 |
| NCT01204710 | Completed | Phase 2 | A Study of Olaratumab (IMC-3G3) in Prostate Cancer | October 2010 | October 2013 |
| NCT01594918 | Completed | Phase 1 | Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer | June 2012 | June 23, 2017 |
| NCT01681537 | Completed | Phase 1 | Lenalidomide Plus Chemotherapy for AML | September 2012 | December 2015 |
| NCT01700946 | Completed | Phase 2 | Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma | April 15, 2013 | July 24, 2021 |
| NCT01830777 | Completed | Phase 1 | Brentuximab Vedotin + Re-induction Chemotherapy for AML | May 2013 | May 2019 |
| NCT01842672 | Completed | Phase 1/Phase 2 | Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia | March 2013 | September 2022 |
| NCT02043756 | Completed | Phase 1 | Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection | August 2011 | August 2013 |
| NCT02200978 | Completed | Phase 4 | A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia | September 2011 | October 2021 |
| NCT02306291 | Completed | Phase 1/Phase 2 | Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML | March 2015 | May 2018 |
| NCT02400281 | Completed | Phase 1/Phase 2 | Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients | September 2015 | July 15, 2020 |
| NCT02523976 | Completed | Phase 2 | Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | August 1, 2015 | December 31, 2021 |
| NCT02583893 | Completed | Phase 2 | Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia | October 7, 2015 | May 17, 2023 |
| NCT02626338 | Completed | Phase 1/Phase 2 | Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML | February 2016 | February 2018 |
| NCT02728050 | Completed | Phase 1/Phase 2 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | December 1, 2016 | April 4, 2023 |
| NCT02937285 | Completed | Phase 3 | National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis | December 6, 2010 | May 28, 2020 |
| NCT03118466 | Completed | Phase 2 | Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia | September 25, 2017 | August 18, 2021 |
| NCT03441048 | Completed | Phase 1 | Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia | May 22, 2018 | May 22, 2024 |
| NCT03563560 | Completed | Phase 1 | A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia | May 15, 2018 | March 31, 2020 |
| NCT04778410 | Completed | Phase 2 | Study of Magrolimab Combinations in Participants With Myeloid Malignancies | June 28, 2021 | March 1, 2024 |
| NCT06007911 | Not yet recruiting | Phase 1 | Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | May 15, 2024 | April 2027 |
| NCT06429449 | Not yet recruiting | Phase 1 | Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia | December 2024 | November 2027 |
| NCT06262438 | Recruiting | Phase 2 | CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients | February 6, 2024 | June 2032 |
| NCT02724163 | Recruiting | Phase 3 | International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia | April 2016 | December 2032 |
| NCT05313958 | Recruiting | Phase 2/Phase 3 | Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children | December 1, 2021 | March 30, 2026 |
| NCT03250338 | Recruiting | Phase 3 | Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML | June 5, 2018 | October 2024 |
| NCT03591510 | Recruiting | Phase 2 | A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML | March 13, 2019 | February 15, 2029 |
| NCT03926624 | Recruiting | Phase 3 | Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage | November 22, 2019 | December 2022 |
| NCT05848687 | Recruiting | Phase 1/Phase 2 | TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | November 3, 2023 | December 2033 |
| NCT04375631 | Recruiting | Phase 1 | CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | December 3, 2020 | December 31, 2027 |
| NCT04195945 | Recruiting | Phase 2 | CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | March 11, 2020 | December 31, 2027 |
| NCT04797767 | Suspended | Phase 1 | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | February 4, 2022 | December 31, 2024 |
| NCT00385827 | Terminated | Phase 2 | A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) | November 2006 | November 2008 |
| NCT00562965 | Terminated | Phase 3 | Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) | November 2007 | April 2011 |
| NCT00660036 | Terminated | Phase 1 | Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia | September 2008 | April 2011 |
| NCT02631252 | Terminated | Phase 1 | Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia | August 18, 2016 | October 2, 2017 |
| NCT00219908 | Terminated | Phase 2 | Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis | July 1999 | June 2006 |
| NCT00882076 | Terminated | Phase 1 | Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias | March 2009 | March 2011 |
| NCT00901927 | Terminated | Phase 2 | Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma | May 2009 | January 2016 |
| NCT01027923 | Terminated | Phase 1 | IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML) | May 2010 | September 2011 |
| NCT01144403 | Terminated | Phase 2 | A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma. | June 2010 | August 2014 |
| NCT00447473 | Terminated | Phase 2 | Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer | July 2006 | September 2008 |
| NCT02198482 | Terminated | Phase 2 | Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | February 2016 | November 2016 |
| NCT00416910 | Terminated | Phase 3 | Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | July 1999 | September 2007 |
| NCT04196010 | Terminated | Phase 1 | Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms | May 8, 2020 | October 13, 2021 |
| NCT02419755 | Terminated | Phase 2 | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | April 14, 2015 | December 31, 2016 |
| NCT02518750 | Terminated | Phase 2 | Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma | November 23, 2016 | March 11, 2018 |
| NCT02520011 | Terminated | Phase 2 | Alvocidib Biomarker-driven Phase 2 AML Study | March 14, 2016 | February 12, 2020 |
| NCT00452387 | Terminated | Phase 2 | Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) | May 2007 | January 2009 |
| NCT00477087 | Terminated | Phase 2 | Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer | July 2006 | January 2010 |
| NCT00510887 | Terminated | Phase 2 | Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma | January 2007 | September 2013 |
| NCT02535806 | Terminated | Phase 2 | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults | July 2015 | May 25, 2017 |
| NCT00146159 | Terminated | Phase 3 | Study Evaluating Mitoxantrone in Multiple Sclerosis | March 2005 | |
| NCT01483690 | Terminated | Phase 1/Phase 2 | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | December 2011 | July 31, 2015 |
| NCT01522443 | Terminated | Phase 3 | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer | March 2012 | January 13, 2015 |
| NCT03735446 | Terminated | Phase 1 | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial | January 18, 2019 | March 29, 2019 |
| NCT03860844 | Terminated | Phase 2 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | August 6, 2019 | May 26, 2023 |
| NCT00180128 | Unknown status | Phase 4 | AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia | January 2000 | November 2012 |
| NCT00499018 | Unknown status | Phase 3 | Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma | January 2006 | September 2013 |
| NCT02848183 | Unknown status | Phase 2 | Optimal Treatment Strategy Based on for Pediatric AML | January 2016 | |
| NCT04024241 | Unknown status | Medium Dose of Cytarabine and Mitoxantrone | September 1, 2017 | August 31, 2019 | |
| NCT02021825 | Unknown status | Phase 4 | Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders | March 2009 | December 2015 |
| NCT05330377 | Withdrawn | Phase 1 | GM-CLAG in Relapsed/Refractory FLT3-mutated AML | March 2023 | May 30, 2032 |